Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.265 USD | -1.14% | -6.93% | +155.88% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+155.88% | 968M | |
+14.28% | 118B | |
+12.94% | 106B | |
-3.62% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.01% | 15.56B | |
+4.22% | 13.63B | |
+27.59% | 12.27B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Sector Update: Health Care